LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 130

Search options

  1. Article ; Online: Louise Brown und die Zukunft der Reproduktionsmedizin

    Weghofer, A

    Speculum - Zeitschrift für Gynäkologie und Geburtshilfe

    2020  Volume 38, Issue 1, Page(s) 12–16

    MeSH term(s) assistierte Reproduktion, Ausblick, Entwicklung, Geschichte, IVF, Prognose, Reproduktionsmedizin, Zukunft
    Publishing date 20200522
    Document type Article ; Online
    ZDB-ID 848302-4
    ISSN 1810-4797 ; 1011-8772
    ISSN (online) 1810-4797
    ISSN 1011-8772
    Database Krause and Pachernegg publications database

    More links

    Kategorien

  2. Article: Novelle des Fortpflanzungsmedizingesetzes - Die neuen Chancen für Kinderwunschpaare

    Weghofer, A.

    Gyn-aktiv

    2016  Volume -, Issue 1, Page(s) 30

    Language German
    Document type Article
    ZDB-ID 2213296-X
    ISSN 1605-8828
    Database Current Contents Medicine

    More links

    Kategorien

  3. Article ; Online: Konzeption und Adipositas

    Weghofer A

    Speculum : Zeitschrift für Gynäkologie und Geburtshilfe, Vol 30, Iss 2, Pp 20-

    2012  Volume 23

    Keywords Adipositas ; Infertilität ; Gynecology and obstetrics ; RG1-991 ; Medicine ; R
    Language German
    Publishing date 2012-01-01T00:00:00Z
    Publisher Krause & Pachernegg GmbH
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Konzeption und Adipositas

    Weghofer, A.

    Speculum

    2012  Volume 30, Issue 2, Page(s) 20

    Language German
    Document type Article
    ZDB-ID 848302-4
    ISSN 1011-8772
    Database Current Contents Medicine

    More links

    Kategorien

  5. Article ; Online: Konzeption und Adipositas

    Weghofer, A

    Speculum - Zeitschrift für Gynäkologie und Geburtshilfe

    2012  Volume 30, Issue 2, Page(s) 20–23

    MeSH term(s) Adipositas, Infertilität
    Publishing date 20120525
    Document type Article ; Online
    ZDB-ID 848302-4
    ISSN 1810-4797 ; 1011-8772
    ISSN (online) 1810-4797
    ISSN 1011-8772
    Database Krause and Pachernegg publications database

    More links

    Kategorien

  6. Article ; Online: Immunocompetent PDMS-Free Organ-on-Chip Model of Cervical Cancer Integrating Patient-Specific Cervical Fibroblasts and Neutrophils.

    Kromidas, Elena / Geier, Alicia / Weghofer, Adrian / Liu, Hui-Yu / Weiss, Martin / Loskill, Peter

    Advanced healthcare materials

    2023  , Page(s) e2302714

    Abstract: Despite preventive measures and available treatments, cervical cancer still ranks as the fourth most prevalent cancer among women worldwide and remains the leading cause of cancer death in women in many developing countries. To gain further insights into ...

    Abstract Despite preventive measures and available treatments, cervical cancer still ranks as the fourth most prevalent cancer among women worldwide and remains the leading cause of cancer death in women in many developing countries. To gain further insights into pathogenesis and to develop novel (immuno)therapies, more sophisticated human models recreating patient heterogeneities and including aspects of the tumor microenvironment are urgently required. A novel polydimethylsiloxane-free microfluidic platform, designed specifically for the generation and ccultivation of cervical cancerous tissue, is introduced. The microscale open-top tissue chambers of the cervical cancer-on-chip (CCoC) enable facile generation and long-term cultivation of SiHa spheroids in co-culture with donor-derived cervical fibroblasts. The resulting 3D tissue emulates physiological architecture and allows dissection of distinct effects of the stromal tissue on cancer viability and growth. Treatment with cisplatin at clinically-relevant routes of administration and dosing highlights the platform's applicability for drug testing. Moreover, the model is amenable for integration and recruitment of donor-derived neutrophils from the microvasculature-like channel into the tissue, all while retaining their ability to produce neutrophil extracellular traps. In the future, the immunocompetent CCoC featuring donor-specific primary cells and tumor spheroids has the potential to contribute to the development of new (immuno)therapeutic options.
    Language English
    Publishing date 2023-11-29
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2649576-4
    ISSN 2192-2659 ; 2192-2640
    ISSN (online) 2192-2659
    ISSN 2192-2640
    DOI 10.1002/adhm.202302714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The ovarian sensitivity index is predictive of live birth chances after IVF in infertile patients.

    Weghofer, A / Barad, D H / Darmon, S K / Kushnir, V A / Albertini, D F / Gleicher, N

    Human reproduction open

    2020  Volume 2020, Issue 4, Page(s) hoaa049

    Abstract: Study question: Does the ovarian sensitivity index (OSI) predict embryo quality, pregnancy and live birth in patients undergoing FSH/hMG stimulation for IVF?: Summary answer: The OSI is predictive of pregnancy and live birth in older women with a ... ...

    Abstract Study question: Does the ovarian sensitivity index (OSI) predict embryo quality, pregnancy and live birth in patients undergoing FSH/hMG stimulation for IVF?
    Summary answer: The OSI is predictive of pregnancy and live birth in older women with a more unfavorable prognosis undergoing FSH/hMG stimulation for IVF.
    What is known already: The OSI was previously reported to reflect gonadotrophin requirements among high, normal and poor responders and to predict pregnancy potential in younger patients undergoing ovarian stimulation with FSH.
    Study design size duration: A retrospective cohort study that included 1282 women undergoing IVF with FSH/hMG stimulation was carried out between January 2010 and December 2016.
    Participants/materials setting methods: We evaluated 1282 women who underwent fertility treatment with FSH/hMG stimulation and oocyte retrieval at an academically affiliated private fertility center. OSI was calculated as (oocytes ×1000)/total gonadotrophin dose and grouped into two classes based on a receiver operating characteristic (ROC) curve analysis of a randomly selected development sample comprising one-third of the cycles. The remaining cycles comprised the validation group. ROC curves were also used to compare the predictive value of OSI to that of baseline FSH and anti-Müllerian hormone (AMH). Logistic regression models evaluated the effect of high (OSI >0.83) and low (OSI ≤0.83) on clinical pregnancy and live birth in the validation group. Models were adjusted for female age, baseline FSH, AMH and oocyte yield and gonadotrophin dose.
    Main results and the role of chance: Women presented with a mean ±SD age of 38.6 ± 5.4 years and showed median AMH levels of 0.65 (95% CI 0.61-0.74) ng/ml. They received 5145 ± 2477 IU of gonadotrophins and produced a median 5.2 (95% CI 5.0-5.5) oocytes. Pregnancy and live birth rates per oocyte retrieval for all women were 20.6% and 15.8%, respectively. Patients with higher OSI (less gonadotrophin required per oocyte retrieved) produced significantly more high-quality embryos than patients with low OSI (3.5 (95% CI 3.2-3.8) versus 0.6 (95% CI 0.5-0.7) (
    Limitations reasons for caution: The results may not be applicable to women with excellent pregnancy potential or FSH-only stimulation.
    Wider implications of the findings: The predictive capacity of OSI for embryo quality, pregnancy and live birth, which is independent of AMH or FSH, may help in counseling patients about their pregnancy potential and live birth chances.
    Study funding/competing interests: Intramural funding from the Center for Human Reproduction and the Foundation for Reproductive Medicine. A.W., V.A.K., D.F.A., D.H.B. and N.G. have received research grant support, travel funds and speaker honoraria from various pharmaceutical and medical device companies: none, however, related to the topic presented here. D.H.B. and N.G. are listed as inventors on already awarded and still pending US patents, claiming beneficial effects on diminished ovarian reserve and embryo ploidy from dehydroepiandrosterone supplementation.
    Trial registration number: N/A.
    Language English
    Publishing date 2020-12-22
    Publishing country England
    Document type Journal Article
    ISSN 2399-3529
    ISSN (online) 2399-3529
    DOI 10.1093/hropen/hoaa049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Rate of rebound in follicle growth after cessation of ovarian stimulation in initial non-responders: a prospective cohort study.

    Gleicher, Norbert / Weghofer, Andrea / Darmon, Sarah K / Barad, David H

    Journal of ovarian research

    2021  Volume 14, Issue 1, Page(s) 11

    Abstract: Previously anecdotally observed rebounds in follicle growth after interruption of exogenous gonadotropins in absolute non-responders were the impetus for here reported study. In a prospective cohort study, we investigated 49 consecutive patients, ... ...

    Abstract Previously anecdotally observed rebounds in follicle growth after interruption of exogenous gonadotropins in absolute non-responders were the impetus for here reported study. In a prospective cohort study, we investigated 49 consecutive patients, absolutely unresponsive to maximal exogenous gonadotropin stimulation, for a so-called rebound response to ovarian stimulation. A rebound response was defined as follicle growth following complete withdrawal of exogenous gonadotropin stimulation after complete failure to respond to maximal gonadotropin stimulation over up to 5-7 days. Median age of study patients was 40.5 ± 5.1 years (range 23-52). Women with and without rebound did not differ significantly (40.0 ± 6.0 vs. 41.0 ± 7.0 years, P = 0.41), with 24 (49.0%) recording a rebound and 25 (51.0%) not. Among the former, 21 (87.5%) reached retrieval of 1-3 oocytes and 15 (30.6%) reached embryo transfer. A successful rebound in almost half of prior non-responders was an unsuspected response rate, as was retrieval of 1-3 oocytes in over half of rebounding patients. Attempting rebounds may, thus, represent another incremental step in very poor prognosis patients before giving up on utilization of autologous oocytes. Here presented findings support further investigations into the underlying physiology leading to such an unexpectedly high rebound rate.
    MeSH term(s) Adult ; Cohort Studies ; Female ; Humans ; Middle Aged ; Ovarian Follicle/metabolism ; Ovulation Induction/methods ; Prospective Studies ; Young Adult
    Language English
    Publishing date 2021-01-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2455679-8
    ISSN 1757-2215 ; 1757-2215
    ISSN (online) 1757-2215
    ISSN 1757-2215
    DOI 10.1186/s13048-021-00765-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: In-vitro-Fertilisation - State of the Art

    Weghofer, Andrea

    Arzt & Praxis

    2014  Volume 68, Issue 1005, Page(s) 169

    Language German
    Document type Article
    ZDB-ID 1224197-0
    ISSN 0048-5128
    Database Current Contents Medicine

    More links

    Kategorien

  10. Article: 2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction.

    Poppe, Kris / Bisschop, Peter / Fugazzola, Laura / Minziori, Gesthimani / Unuane, David / Weghofer, Andrea

    European thyroid journal

    2021  Volume 9, Issue 6, Page(s) 281–295

    Abstract: Severe thyroid dysfunction may lead to menstrual disorders and subfertility. Fertility problems may persist even after restoring normal thyroid function, and then an assisted reproductive technology (ART) may be a solution. Prior to an ART treatment, ... ...

    Abstract Severe thyroid dysfunction may lead to menstrual disorders and subfertility. Fertility problems may persist even after restoring normal thyroid function, and then an assisted reproductive technology (ART) may be a solution. Prior to an ART treatment, ovarian stimulation is performed, leading to high oestradiol levels, which may lead to hypothyroidism in women with thyroid autoimmunity (TAI), necessitating levothyroxine (LT4) supplements before pregnancy. Moreover, women with the polycystic ovarian syndrome and idiopathic subfertility have a higher prevalence of TAI. Women with hypothyroidism treated with LT4 prior to ART should have a serum TSH level <2.5 mIU/L. Subfertile women with hyperthyroidism planning an ART procedure should be informed of the increased risk of maternal and foetal complications, and euthyroidism should be restored and maintained for several months prior to an ART treatment. Fertilisation rates and embryo quality may be impaired in women with TSH >4.0 mIU/L and improved with LT4 therapy. In meta-analyses that mainly included women with TSH levels >4.0 mIU/L, LT4 treatment increased live birth rates, but that was not the case in 2 recent interventional studies in euthyroid women with TAI. The importance of the increased use of intracytoplasmic sperm injection as a type of ART on pregnancy outcomes in women with TAI deserves more investigation. For all of the above reasons, women of subfertile couples should be screened routinely for the presence of thyroid disorders.
    Language English
    Publishing date 2021-01-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2659767-6
    ISSN 2235-0802 ; 2235-0640
    ISSN (online) 2235-0802
    ISSN 2235-0640
    DOI 10.1159/000512790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top